Suppliers and packagers for precedex

precedex

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038	NDA	Henry Schein, Inc.	0404-9938-02	1 VIAL in 1 BAG (0404-9938-02) / 2 mL in 1 VIAL	2022-01-13
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038	NDA	Hospira, Inc.	0409-0155-02	10 BOTTLE in 1 TRAY (0409-0155-02) / 100 mL in 1 BOTTLE (0409-0155-01)	2023-01-03
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038	NDA	Hospira, Inc.	0409-1174-10	10 BOTTLE in 1 TRAY (0409-1174-10) / 100 mL in 1 BOTTLE (0409-1174-01)	2022-03-07
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038	NDA	Hospira, Inc.	0409-1434-01	1 BOTTLE in 1 CARTON (0409-1434-01) / 250 mL in 1 BOTTLE	2020-09-28
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038	NDA	Hospira, Inc.	0409-1454-20	20 BOTTLE in 1 TRAY (0409-1454-20) / 50 mL in 1 BOTTLE (0409-1454-01)	2022-03-07

Precedex (Dexmedetomidine Hydrochloride) Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the current supplier landscape for Precedex (dexmedetomidine hydrochloride), a sedative and analgesic used in intensive care settings. The analysis focuses on key active pharmaceutical ingredient (API) manufacturers, finished dosage form (FDF) producers, and the regulatory status of primary suppliers.

Who are the Primary Manufacturers of Dexmedetomidine Hydrochloride API?

The production of dexmedetomidine hydrochloride API is concentrated among a limited number of specialized chemical manufacturers. Key players identified include:

• Fresenius Kabi AG: As the originator of Precedex, Fresenius Kabi is a primary manufacturer of the API. Their role is crucial in maintaining supply for their branded product and potentially for generic formulations.
• Hospira, Inc. (a Pfizer company): Hospira, through its generic arm, has been a significant producer of dexmedetomidine hydrochloride API, particularly supporting its generic injectable formulations.
• Various Contract Manufacturing Organizations (CMOs): Several CMOs globally are involved in the synthesis of dexmedetomidine hydrochloride API. These entities often operate under strict quality agreements with pharmaceutical companies. Specific names are typically proprietary, but regions with strong API manufacturing bases, such as India and China, are known to house such capabilities.

What are the Key Finished Dosage Form (FDF) Manufacturers?

The FDF market for dexmedetomidine hydrochloride is characterized by both branded and generic competition.

• Fresenius Kabi AG: Markets the branded product Precedex®. This includes intravenous solutions.
• Hospira, Inc. (a Pfizer company): Manufactures and markets a generic version of dexmedetomidine hydrochloride injection.
• Teva Pharmaceuticals Industries Ltd.: A major generic pharmaceutical company that offers dexmedetomidine hydrochloride injection.
• Mylan N.V. (now Viatris Inc.): Another significant player in the generic injectable market, providing dexmedetomidine hydrochloride injection.
• Amneal Pharmaceuticals LLC: Offers a generic dexmedetomidine hydrochloride injection.
• Sandoz Inc. (Novartis' generics division): A substantial global generic manufacturer with a presence in injectable pharmaceuticals.

The FDF market is dynamic, with new generic entrants emerging as patents expire or face challenges. Competition primarily centers on price, supply chain reliability, and market access.

What is the Regulatory Status of Key Dexmedetomidine Hydrochloride Suppliers?

Regulatory compliance is a critical factor for API and FDF suppliers. Key aspects include:

• United States Food and Drug Administration (US FDA) Approval:
  • Fresenius Kabi's Precedex® has New Drug Application (NDA) approval.
  • Generic versions from manufacturers like Hospira, Teva, Mylan (Viatris), Amneal, and Sandoz have Abbreviated New Drug Application (ANDA) approvals. This signifies equivalence to the reference listed drug (RLD).
  • API suppliers must adhere to Good Manufacturing Practices (GMP). US FDA inspections and facility audits are standard for API manufacturers supplying the US market. Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP) are often sought.
• European Medicines Agency (EMA) Compliance:
  • Similar to the US, EMA oversees the approval of both branded and generic medicines.
  • API manufacturers supplying the EU market typically require a CEP and compliance with EU GMP standards.
• Other Regulatory Bodies: Suppliers must also meet the requirements of other major pharmaceutical markets, including Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA).

Table 1: Key Dexmedetomidine Hydrochloride Suppliers (API & FDF)

Company Name	Primary Role (API/FDF)	Key Products/Brands	Market Presence	Regulatory Notes
Fresenius Kabi AG	API & FDF	Precedex®	Global	NDA Holder (US), EMA approvals. Significant API manufacturing capability.
Hospira, Inc. (Pfizer)	API & FDF	Generic Dexmedetomidine HCl	Global	ANDA approvals (US), EMA approvals for generic. Established API and FDF manufacturing.
Teva Pharmaceuticals	FDF	Generic Dexmedetomidine HCl	Global	ANDA approvals (US), EMA approvals. Relies on third-party API suppliers, subject to rigorous qualification.
Viatris Inc. (Mylan)	FDF	Generic Dexmedetomidine HCl	Global	ANDA approvals (US), EMA approvals. Sourcing API from qualified global suppliers.
Amneal Pharmaceuticals	FDF	Generic Dexmedetomidine HCl	US primarily	ANDA approvals (US). Focus on US market.
Sandoz Inc. (Novartis)	FDF	Generic Dexmedetomidine HCl	Global	ANDA approvals (US), EMA approvals. Extensive global generic injectable portfolio.
Various CMOs	API	Dexmedetomidine HCl API	Global (Sourcing)	Must meet GMP standards of importing regulatory bodies (FDA, EMA). Often operate under confidential agreements.

What are the Supply Chain Considerations for Dexmedetomidine Hydrochloride?

The supply chain for dexmedetomidine hydrochloride involves several critical points:

• API Sourcing: Pharmaceutical companies producing generic dexmedetomidine HCl injections must secure a reliable and GMP-compliant API source. This involves stringent vendor qualification processes, including audits of manufacturing facilities and quality control systems.
• Manufacturing Capacity: The injectable drug market requires specialized sterile manufacturing facilities. Ensuring sufficient capacity for both API and FDF production is essential to meet demand and prevent shortages, especially given the drug's use in critical care.
• Geopolitical Factors: Reliance on API manufacturers in specific geographic regions can expose the supply chain to geopolitical risks, trade disputes, or localized regulatory changes. Diversification of API sourcing is a common risk mitigation strategy.
• Logistics and Cold Chain: While dexmedetomidine hydrochloride does not typically require strict cold chain storage, robust logistics are necessary to ensure timely delivery to hospitals and healthcare facilities.

What are the Patent and Exclusivity Landscapes?

The patent landscape for dexmedetomidine hydrochloride is crucial for understanding generic competition.

• Originator Patents: Fresenius Kabi's original patents for dexmedetomidine hydrochloride and its use as a sedative expired years ago, paving the way for generic entry.
• Formulation and Method of Use Patents: Pharmaceutical companies may hold secondary patents covering specific formulations, new indications, or methods of administration. These can extend market exclusivity for certain uses or dosage forms. For example, extended-release formulations or specific infusion protocols could be patented.
• Generic Exclusivity: Upon successful ANDA approval, generic manufacturers can achieve market exclusivity for a period, depending on regulatory pathways (e.g., Hatch-Waxman Act provisions in the US).

The current market is largely dominated by generic competition, with pricing being a primary differentiator.

What are the Potential Risks and Opportunities in the Dexmedetomidine Hydrochloride Market?

Risks:

• Supply Chain Disruptions: Reliance on a limited number of API manufacturers or unexpected plant closures can lead to shortages.
• Increased Regulatory Scrutiny: More stringent GMP requirements or new quality standards could increase compliance costs for manufacturers.
• Price Erosion: Intense generic competition can lead to significant price reductions, impacting profitability for all market participants.
• Emergence of Alternative Sedatives: Development of novel sedatives or analgesics with superior profiles could diminish the market share of dexmedetomidine hydrochloride.

Opportunities:

• Emerging Markets: Expansion into developing countries where critical care infrastructure is growing presents an opportunity for both branded and generic suppliers.
• New Formulations or Delivery Systems: Research into alternative delivery methods or combination products could create new market segments or extend product life cycles.
• Supply Chain Resilience: Companies that can demonstrate robust and diversified supply chains may gain a competitive advantage by assuring reliable supply.
• Cost Optimization: For generic manufacturers, optimizing API sourcing and manufacturing processes can lead to significant cost savings and competitive pricing.

Key Takeaways

The dexmedetomidine hydrochloride market is characterized by established branded and generic suppliers, with a significant portion of API manufacturing concentrated among specialized chemical producers. Regulatory compliance, particularly GMP adherence and successful navigation of US FDA and EMA approvals, is paramount for all participants. Supply chain resilience and cost-effective manufacturing are critical competitive factors in the predominantly generic FDF market.

Frequently Asked Questions

1. Is Fresenius Kabi the sole supplier of dexmedetomidine hydrochloride API? No, while Fresenius Kabi is a primary API manufacturer, other specialized API producers and contract manufacturing organizations also synthesize dexmedetomidine hydrochloride API, often supplying generic drug manufacturers.
2. What is the primary regulatory hurdle for new API suppliers entering the dexmedetomidine hydrochloride market? The primary hurdle is demonstrating consistent adherence to Good Manufacturing Practices (GMP) as required by regulatory bodies like the US FDA and EMA, and successfully undergoing facility inspections and audits.
3. How do generic dexmedetomidine hydrochloride manufacturers ensure API quality? Generic manufacturers implement rigorous supplier qualification programs, conduct regular site audits of their API vendors, and perform extensive in-house testing of incoming API batches to verify quality and compliance.
4. Are there any significant patent protections remaining for dexmedetomidine hydrochloride that could limit generic competition? While the primary patents have expired, secondary patents related to specific formulations, novel delivery methods, or new therapeutic uses could still exist, potentially impacting the market for specific product variations.
5. What are the primary risks associated with sourcing dexmedetomidine hydrochloride API from China or India? Primary risks include potential supply chain disruptions due to geopolitical factors or localized regulatory changes, the need for stringent quality control to ensure GMP compliance, and potential intellectual property concerns.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book [2] European Medicines Agency. (n.d.). Human medicines. Retrieved from https://www.ema.europa.eu/en/human-medicines [3] Company Websites and Public Filings (Fresenius Kabi AG, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., Viatris Inc., Amneal Pharmaceuticals LLC, Sandoz Inc.). (Accessed 2023-2024). [4] Pharmaceutical Industry Market Research Reports (Various). (Cited implicitly for market dynamics and supplier identification).